- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Potentially Undervalued Companies
Australian Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
38
Companies with a Value score of at least 3, ordered by Value score
38 companies
Trajan Group Holdings
Market Cap: AU$126.5m
Develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.82
7D
-1.8%
1Y
-6.8%
Aroa Biosurgery
Market Cap: AU$162.1m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.47
7D
6.9%
1Y
-14.7%
Aroa Biosurgery
Market Cap: AU$162.1m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.53
7D
20.5%
1Y
-3.6%
Trajan Group Holdings
Market Cap: AU$126.5m
Develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.80
7D
-5.9%
1Y
-11.1%
Medical Developments International
Market Cap: AU$72.1m
Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.
MVP
AU$0.63
7D
8.6%
1Y
34.0%
EZZ Life Science Holdings
Market Cap: AU$74.1m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.
EZZ
AU$1.57
7D
-3.4%
1Y
65.6%
Little Green Pharma
Market Cap: AU$33.4m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.10
7D
0%
1Y
-16.0%
Little Green Pharma
Market Cap: AU$33.4m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.10
7D
-13.0%
1Y
-23.1%
AVITA Medical
Market Cap: AU$160.5m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
AVH
AU$1.91
7D
-10.1%
1Y
-31.0%
AVITA Medical
Market Cap: AU$164.2m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
AVH
AU$2.00
7D
-2.4%
1Y
-24.8%
Medical Developments International
Market Cap: AU$72.1m
Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.
MVP
AU$0.65
7D
6.6%
1Y
51.2%
Neuren Pharmaceuticals
Market Cap: AU$1.7b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$14.13
7D
10.0%
1Y
-31.8%
Neuren Pharmaceuticals
Market Cap: AU$1.7b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$13.86
7D
7.4%
1Y
-34.2%
EZZ Life Science Holdings
Market Cap: AU$74.1m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.
EZZ
AU$1.54
7D
-1.6%
1Y
56.6%
Radiopharm Theranostics
Market Cap: AU$58.3m
Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
RAD
AU$0.024
7D
11.6%
1Y
-29.4%
Clinuvel Pharmaceuticals
Market Cap: AU$549.1m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$10.92
7D
3.4%
1Y
-27.9%
Mayne Pharma Group
Market Cap: AU$305.4m
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYXDA
AU$3.47
7D
-9.4%
1Y
n/a
CSL
Market Cap: AU$119.7b
Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$247.13
7D
1.1%
1Y
-11.4%
Biotron
Market Cap: AU$4.0m
A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
BIT
AU$0.0025
7D
0%
1Y
-95.8%
CSL
Market Cap: AU$119.7b
Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$248.00
7D
0.6%
1Y
-10.9%
Radiopharm Theranostics
Market Cap: AU$58.3m
Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
RAD
AU$0.023
7D
9.5%
1Y
-30.3%
NeuroScientific Biopharmaceuticals
Market Cap: AU$7.5m
Engages in the research and development of novel peptide-based pharmaceutical products.
NSB
AU$0.051
7D
-7.3%
1Y
21.4%
Biotron
Market Cap: AU$4.0m
A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
BIT
AU$0.003
7D
20.0%
1Y
-94.6%
Clinuvel Pharmaceuticals
Market Cap: AU$549.1m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$10.97
7D
4.0%
1Y
-28.6%
Mayne Pharma Group
Market Cap: AU$305.4m
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYXDA
AU$3.54
7D
-9.2%
1Y
n/a
NeuroScientific Biopharmaceuticals
Market Cap: AU$7.5m
Engages in the research and development of novel peptide-based pharmaceutical products.
NSB
AU$0.058
7D
9.4%
1Y
16.0%
Mesoblast
Market Cap: AU$2.2b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$1.67
7D
-1.5%
1Y
50.0%
Cynata Therapeutics
Market Cap: AU$40.7m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.18
7D
-5.1%
1Y
-42.2%
Mesoblast
Market Cap: AU$2.2b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$1.68
7D
-0.6%
1Y
36.6%
Telix Pharmaceuticals
Market Cap: AU$8.9b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
TLX
AU$26.26
7D
2.2%
1Y
67.3%
Cryosite
Market Cap: AU$36.6m
Provides outsourced clinical trials logistic services in Australia.
CTE
AU$0.75
7D
-1.3%
1Y
-31.8%
Cynata Therapeutics
Market Cap: AU$40.7m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.18
7D
-5.3%
1Y
-43.8%
Mayne Pharma Group
Market Cap: AU$400.5m
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYX
AU$4.93
7D
8.6%
1Y
-1.0%
Actinogen Medical
Market Cap: AU$65.8m
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
ACW
AU$0.021
7D
-2.3%
1Y
-19.2%
Cryosite
Market Cap: AU$36.6m
Provides outsourced clinical trials logistic services in Australia.
CTE
AU$0.74
7D
-0.7%
1Y
n/a
Actinogen Medical
Market Cap: AU$65.8m
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
ACW
AU$0.021
7D
0%
1Y
-27.6%